隶属于 默沙东
相关临床试验
155
149 进行中
药物批准
32
批准总数
监管机构
3
监管机构数
成立时间
1891
进行中（未招募）
149
96.1%
已完成
2
1.3%
招募中
4
2.6%
- Researchers at Purdue University and Merck have developed a patent-pending Raman spectroscopy-based tool that monitors vaccine quality in real-time during production, delivering results in 30 seconds or less. - The tool successfully detected human cytomegalovirus particles at industrially relevant concentrations and flow rates, representing the first reported Raman spectroscopy system of this type for CMV detection. - Unlike current offline testing methods that require sample removal from production lines, this online monitoring system operates continuously during manufacturing, potentially saving time and money in vaccine production. - The technology supports continuous manufacturing processes and could be adapted for monitoring other vaccine types and viral particles in future applications.
- The Supreme Court's decision in _Merck Sharp & Dohme Corp. v. Albrecht_ has significantly impacted preemption defenses in pharmaceutical litigation, particularly concerning failure-to-warn claims. - The Fosamax multidistrict litigation (MDL) has been directly affected, with the initial ruling against certain claims reversed, leading to ongoing legal debate and reinterpretation. - Legal interpretations of preemption, including the FDA's role and the evidence required for conflict preemption, are being actively re-evaluated in light of the _Albrecht_ decision.
